X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (31) 31
female (29) 29
oncology (28) 28
middle aged (27) 27
aged (22) 22
chemotherapy (22) 22
index medicus (22) 22
male (21) 21
adult (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
treatment outcome (13) 13
breast cancer (12) 12
carcinoma, non-small-cell lung - drug therapy (12) 12
disease-free survival (11) 11
lung neoplasms - drug therapy (11) 11
aged, 80 and over (10) 10
hematology, oncology and palliative medicine (10) 10
cancer (9) 9
carcinoma, non-small-cell lung - pathology (9) 9
care and treatment (9) 9
gefitinib (9) 9
metastasis (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
lung neoplasms - pathology (8) 8
survival (8) 8
deoxycytidine - administration & dosage (7) 7
deoxycytidine - analogs & derivatives (7) 7
open-label (7) 7
trial (7) 7
adenocarcinoma (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
breast neoplasms - drug therapy (6) 6
cisplatin - administration & dosage (6) 6
drug administration schedule (6) 6
erlotinib (6) 6
gemcitabine (6) 6
mutation (6) 6
neoplasm metastasis (6) 6
neoplasm staging (6) 6
therapy (6) 6
time factors (6) 6
young adult (6) 6
adolescent (5) 5
cancer therapies (5) 5
carboplatin - administration & dosage (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
cisplatin (5) 5
kaplan-meier estimate (5) 5
lung cancer, non-small cell (5) 5
product development (5) 5
tumors (5) 5
antibodies, monoclonal, humanized - administration & dosage (4) 4
breast neoplasms - metabolism (4) 4
cancer research (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
clinical trials (4) 4
double-blind method (4) 4
drug therapy, combination (4) 4
lung neoplasms - genetics (4) 4
lung neoplasms - mortality (4) 4
multicenter (4) 4
nsclc (4) 4
patients (4) 4
protein kinase inhibitors - administration & dosage (4) 4
quality of life (4) 4
quinazolines - administration & dosage (4) 4
receptor, erbb-2 - metabolism (4) 4
research (4) 4
respiratory system (4) 4
survival rate (4) 4
adjuvant chemotherapy (3) 3
analysis (3) 3
asia (3) 3
breast neoplasms - pathology (3) 3
carboplatin (3) 3
cell lung-cancer (3) 3
chemotherapy, adjuvant (3) 3
colorectal neoplasms - drug therapy (3) 3
combination (3) 3
combined modality therapy (3) 3
drug therapy (3) 3
egfr (3) 3
everolimus (3) 3
guidelines (3) 3
hospitals (3) 3
medical colleges (3) 3
medical prognosis (3) 3
medicine & public health (3) 3
mtor (3) 3
neoadjuvant therapy (3) 3
neoplasm recurrence, local - drug therapy (3) 3
neoplasm recurrence, local - pathology (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
non-small cell lung cancer (3) 3
paclitaxel - administration & dosage (3) 3
pemetrexed (3) 3
prognosis (3) 3
progression-free survival (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 25 - 32
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 791 - 800
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Genes, erbB-1 - drug effects | Lung Neoplasms - drug therapy | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - metabolism | Middle Aged | Far East - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Anaplastic Lymphoma Kinase - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Lung Neoplasms - secondary | Female | Carcinoma, Non-Small-Cell Lung - pathology | Anaplastic Lymphoma Kinase - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Genes, erbB-1 - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Disease-Free Survival | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Slopes | Lung cancer | Oncology | Kinases | Cancer therapies | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Hypothyroidism | Survival | Patients | Medical centres | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Tumors | Apoptosis
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2015, Volume 21, Issue 14, pp. 3196 - 3203
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2/2017, Volume 25, Issue 2, pp. 459 - 464
Journal Article
Journal Article
Breast Cancer, ISSN 1340-6868, 11/2014, Volume 21, Issue 6, pp. 703 - 714
Journal Article
Breast cancer (Dove Medical Press), ISSN 1179-1314, 2019, Volume 11, pp. 43 - 51
The aim of this study was to compare the efficacy and tolerability of BP-C1 vs equal-looking placebo in metastatic breast cancer. A randomized, double-blind,... 
Chemotherapy | Hospitals | Medical prognosis | Conflicts of interest | Hydrocarbons | Breast cancer | Metastasis | Drug resistance | Cancer therapies | Age | stage IV | Benzene-polycarboxylic acid complex | breast cancer | BP-C1 |